Clinical trial
Bevacizumab and Doxorubicin Hydrochloride Liposome in Treating Women With…
NCT00445406 · Swiss Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00445406 |
|---|---|
| Title | Bevacizumab and Doxorubicin Hydrochloride Liposome in Treating Women With Locally Recurrent or Metastatic Breast Cancer |
| Official title | Bevacizumab and Pegylated Liposomal Doxorubicin as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer. A Multicenter, Single-Arm Phase II Trial |
| Lead sponsor | Swiss Cancer Institute, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | bevacizumab + doxorubin hydrochloride liposme, Bevacizumab |
| Enrollment | 43 |
| Start date | Dec 1, 2006 |
| Primary completion | Sep 1, 2008 |
| Completion | Mar 1, 2009 |
| First posted | Mar 9, 2007 |
| Last update posted | Jun 28, 2012 |
| Countries | Switzerland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: